Compare IDEXX Laboratories, Inc. (IDXX) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Sea Limited — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Sea Limited trades at $131.4 (market cap $80.55B). The key difference: Sea Limited is the larger of the two by market cap, and Sea Limited is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | SE | |
|---|---|---|
Market Cap | $46.22B | $80.55B |
Sector | Health | Media |
52-Week High | $766.68 | $196.50 |
52-Week Low | $526.44 | $78.16 |
Enterprise Value | $47.12B | $75.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
SE stock trades at $129.71, up 12.99% on strong Q2 2026 results, with revenue of $7.8 billion (up 48% year-over-year) and net income of $458 million (up 11%). The technical picture is bullish with moving averages supporting the uptrend, though RSI levels indicate overbought conditions. Fundamentals show robust revenue growth and improving profitability, with net income margin reaching 6.36% in 2025. Analyst sentiment remains positive with a consensus buy rating and $128.33 price target.
The outlook for SE is favorable given accelerating growth across e-commerce, fintech, and gaming segments, but risks include margin pressure from increased investments and credit costs. The stock's high valuation multiples (P/E of 50.78) require sustained execution to justify further gains. Near-term resistance lies at $133, with support at $128.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
